Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on our proprietary technology for controlling biological replication, is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. 1 -------------------------------------------------------------------------------- Table of Contents We have worldwide rights for our INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received CE marks and are being marketed and sold in a number of countries around the world including those in Europe, The Commonwealth of Independent States, or CIS, and the Middle East. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-0.37 |
| Quarterly EPS Est: | -0.09 |
| PEG Ratio: | -.01 |
|
Mean Recommendation: View Summary / View All |
1 |
Data is provided by Zacks Investment Research

